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Abstract
Background: Astrocytic brain tumors are among the most lethal and morbid tumors of adults,
often occurring during the prime of life. These tumors form an interesting group of cancer to
understand the molecular mechanism of pathogenesis. Histological grading of Astrocytoma based
on WHO classification does not provide complete information on the proliferation potential and
biological behavior of the tumors. It is known that cancer results from the disruption of the orderly
regulated cycle of replication and division. In the present study, we made an attempt to identify the
cell cycle signatures and their involvement in the clinical aggressiveness of gliomas.
Methods: The variation in expression of various cell cycle genes was studied in different stages of
glial tumor progression (low and high grades), and the results were compared with their
corresponding expression levels in the normal brain tissue. Macroarray analysis was used for the
purpose.
Results:  Macroarray analysis of 114 cell cycle genes in different grades of glioma indicated
differential expression pattern in 34% of the gene transcripts, when compared to the normal tissue.
Majority of the transcripts belong to the intracellular kinase networks, cell cycle regulating kinases,
transcription factors and transcription activators.
Conclusion: Based on the observation in the expression pattern in low grade and high grade
gliomas, it can be suggested that the upregulation of cell cycle activators are seen as an early event
in glioma; however, in malignancy it is not the cell cycle activators alone, which are involved in
tumorigenesis. Understanding the molecular details of cell cycle regulation and checkpoint
abnormalities in cancer could offer an insight into potential therapeutic strategies.
Background
Gliomas are the most common primary brain tumors.
These ectodermal primary brain tumors form ~50% of all
intracranial tumors. They can occur at any age, especially
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young to middle age, and are comparatively more com-
mon in men. Gliomas can be subtyped as astrocytic, oli-
godendroglial, or ependymal. They may be classified as
low-grade (WHO grade II), anaplastic (WHO grade III), or
glioblastoma multiforme (WHO grade IV), in the order of
increasing malignancy [1]. Currently, these classifications
are based on the observed histopathological characteris-
tics of the tumor such as nuclear atypia, mitotic activity,
cellularity, vascular proliferation and necrosis [2]. Malig-
nancy grades are pathologically determined and are some-
times subjective and inconsistent. Several molecular
genetic and cell biological data have helped to identify
some of the genes involved in the oncogenesis and pro-
gression of gliomas [3-5].
The classification of malignant gliomas remains contro-
versial, and effective therapies have been elusive; hence,
primary brain tumors have come under intense scientific
scrutiny in the recent years [6,7]. It is known that cancers
have very complex patterns of differential gene expres-
sion, and are confounded by multiple environmental var-
iables of carcinogenesis [8]. Therefore, the study of single
gene at single time point in the progression of a tumor
may provide only limited information towards our under-
standing of the bigger picture of cancer. Most of the can-
cers result from the disruption of the orderly regulated
cycle of cell replication and division. Different stages of
cell cycle are programmed by the cell cycle clock via a vari-
ety of gene products [9]. It is stimulated by the products of
proto-oncogenes and is under the negative control of
tumor suppressor genes. Malignancies in cancer result
from imbalance in control caused by increased effect of
proliferation promoting factors i.e. oncogenes or decrease
in inhibition, namely tumor suppressor genes [10]. A
mutation in one of these genes can lead to cancerous
condition.
Recently, a more comprehensive pathway-specific
approach has been developed, which includes analysis of
differential gene expression, reflecting regulatory differ-
ences [12]. In general gliomas are believed to have a linear
grade of progression towards malignancy. In the present
study, we seek to identify differentially expressed cell cycle
genes relevant for tumor development and malignant
transformation, in order to gain insights into the molecu-
lar mechanisms of Glial tumor progression and uncover
new therapeutic targets.
Methods
Sample Collection
Fresh biopsy samples of glioma were collected in steri-
lized tubes containing RNAse inhibitor, from the Dept. of
Neurosurgery, SCTIMST. Three samples in each grade,
with similar age and pathological features, were consid-
ered in the present study in order to minimize tissue het-
erogeneity and the influence of other variables for the
cause of the disease. Normal glial tissue was obtained
from the autopsy of a head injury patient. All the samples
were collected as per the institutional ethical committee
guidelines. The gliomas were pathologically diagnosed
and the regions of pleomorphism were identified and sur-
gically scraped to avail maximum tumor cell population.
The variation in expression of the various cell cycle genes
was studied in different stages of glial tumor progression
(low and high grades), and the results were compared
with their corresponding expression levels in the normal
brain tissue. The macroarray differential display method,
which is known for its excellent throughput and outstand-
ing expression analysis capability, was used for the pur-
pose (Clontech Atlas Cell Cycle Array kit 7748).
RNA extraction
Total RNA was extracted from the tissue sample by the
standard TRIzol method (Invitrogen). The RNA sample
was digested with DNAse I (10 U/µg) to remove DNA con-
tamination, which might lead to false positivity during
hybridization. After digestion, DNAse was removed from
the sample by phenol-chloroform extraction, followed by
ethanol precipitation. The RNA sample was stored in -
70°C till use. The quantity and quality of the purified
total RNA was estimated in a UV-spectrophotometer.
Poly A+ enrichment
Poly A+ enrichment was done using CLONTECH mRNA
extraction kit (7748), as per the manufacturer's protocol.
The first strand of cDNA was synthesized using bioti-
nylated oligo (dT). Poly A+ RNA (mRNA) was separated
from the total RNA pool using streptavidin-coated mag-
netic beads.
cDNA probe synthesis
cDNAs were synthesized using the CDS primer mix
(CLONTECH Atlas Human Cell Cycle CDS primer mix
7748-CDS). α-32P dATP was included in the cDNA syn-
thesis reaction to facilitate probe labeling. The labeled
cDNAs were column-purified using the Atlas NucleoSpin
Extraction Kit. The purified labeled probes were stored in
-20°C till use.
Hybridization
The labeled cDNA probes were hybridized to the macroar-
ray nylon membrane (Atlas Human Cell Cycle Array
7748-1) according to the manufacturer's protocol.
ExpressHyb solution was used for hybridization, with
sheared salmon testes DNA as the blocking agent. Along
with the probe, Cot-1 DNA was added to block hybridiza-
tion to repetitive DNA, which might be present in the
array. Hybridization was carried out at 68°C for 18 hrs.
Following hybridization, the membrane was washed
thrice in wash solution I (2 × SSC, 1% SDS), and once inJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/11
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wash solution II (0.1 × SSC, 0.5% SDS). All the washings
were carried out at 68°C for 30 min each. The membrane
was finally rinsed in 2 × SSC, wrapped in a Saran wrap and
exposed to a phosphor imager screen. The membrane was
exposed for 3–4 hrs and the image was documented in a
Phosphor Imager (BIO-RAD).
Membrane stripping
The macroarray membrane was stripped and reused for a
maximum of three times. The membrane was boiled in
0.5% SDS for 10 min. It was then cooled and rinsed in
wash solution I. The membrane was wrapped in a Saran
wrap and stored in -20°C.
Analysis
The resultant macroarray spots were normalized by a two
step normalization process in order to control the back-
ground and have uniform signal intensity. Background
normalization was done by checking the signal intensities
of negative controls; normalization for uniform signal
intensity was evaluated against known "housekeeping
genes" in the expression array that have a known, stable
binding efficiency. Expression uniformity among the
housekeeping genes was observed in all the hybridization
experiments. The qualitative scores of differential expres-
sion assigned to each transcript measurement were
according to the following system: The fold increase (+) or
decrease (-) in the range of (+/-) 0–0.5 were considered as
No Change (NC), (+/-) 0.6–2.0 as Marginally Increased
(MI) or Marginally Decreased (MD) and (+/-) 2.0 and
above as Increased (I) or Decreased (D). Heterogeneity of
expression within the grades was considered only when
the expression differed by a minimal threshold of two
fold.
Results
Transcriptional Assay of Cell cycle genes
Transcriptional assay of 114 cell cycle genes and 7 house-
keeping genes were done using a macroarray system for
astrocytoma grade II, anaplastic astrocytoma and normal
Glial tissue (Fig 1). Differential expression pattern was
observed in 39 (34%) gene transcripts in glioma when
compared to normal tissue. Majority of these transcripts
belong to intracellular kinase networks, cell cycle regulat-
ing kinases, transcription factors and transcription activa-
tors. 28 (24.5%) transcripts showed overexpression in low
grade gliomas and seven (6%) transcript showed
decreased expression (Appendix). However, in high grade
gliomas 16 (14%) transcripts showed down regulation
while 5 (4.3%) transcripts showed increased expression.
Six of the overexpressed transcripts of low grade gliomas
reversed to decreased expression in high grade (Fig 2).
In low-grade gliomas, upregulation of transcription fac-
tors and transcription activators were observed. Among
the overexpressed intracellular kinase network transcripts,
MAP Kinases form a major cluster of which, MAP Kinase
12 (15%) and MAP Kinase p38 beta (50%) contribute the
most. Junction Plakoglobin, a cytoskeletal protein was
Macroarray profiles of cell cycle genes in different grades of  Glial tumors Figure 1
Macroarray profiles of cell cycle genes in different grades of 
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Upregulated and downregulated transcripts of expression in cell cycle genes Figure 2
Upregulated and downregulated transcripts of expression in cell cycle genesJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/11
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observed to have very high level of expression in low
grade gliomas (91-fold). Other significantly upregulated
transcripts in low grade gliomas include replication factor
C3 (RFC3), jun B proto oncogene, GADD45, Chromatin
Assembly factor1 p48 subunit, purine-rich element bind-
ing protein A and RBQ retinoblastoma-binding protein.
Downregulated transcripts in low grades include CDK10,
akt-proto oncogene and CDC37. In high grade gliomas,
none of the functional clusters showed predominance of
expression patterns. Significant upregulation was
observed in CDKN1A, CDK5 and PCTAIRE protein
kinase. Majority of the transcripts showed decreased
expression in high grade, which include Cyclin D (7-fold)
and CDK4 inhibitor 2D (4-fold). Heterogeneity was
observed, but was within the minimal threshold and
therefore, is not represented in the present data.
Discussion
In the field of neuro-oncology, new methods are desper-
ately needed to complement current methods for disease
detection, tumor grading, and determination of response
to brain tumor therapy [11,12]. Conventional analysis of
expression using Northern Blotting, RT-PCR methods [13]
and gel based differential display methods are cumber-
some, time consuming and very low throughput methods.
In the present study, an attempt has been made to under-
stand the involvement of different cell cycle genes in vari-
ous grades of gliomas using a macroarray system. DNA
microarray method provides a tool for massive parallel
analysis of several genes using cDNAs, ESTs or oligo DNAs
on a glass support; however, this method involves high
system cost and data reliability is still a matter of concern.
On the other hand, the reliability of data interpretation in
filter based macroarray system used in the present study is
very high; it is highly cost effective and uses a very well
proven technology of spotting cDNA on nylon mem-
branes. cDNA arrays can provide the powerful analysis of
differing molecular profiles at various time points in the
progression of the same tumor [14].
Presently, there are neither reliable prognostic indicators
for brain tumors nor any circulating or in situ brain tumor
markers that can be used to determine response to treat-
ment. Earlier studies were based on individual grades of
gliomas and represented wider spectrum of transcripts
[15-18]. The mammalian cell cycle is exquisitely control-
led by a 'machinery' composed of cyclin-dependent
kinases and their binding partners, the cyclins. These
kinases regulate transitions into DNA synthesis and mito-
sis; their inactivity contributes to cellular quiescence, dif-
ferentiation and senescence [19]. Cell cycle transitions
are, in turn, controlled by checkpoints that monitor ribo-
nucleotide pools, oxygen tension, the extracellular envi-
ronment, growth signaling programmes, the status of
DNA replication, and the mitotic spindle apparatus.
Genes positively controlling cell cycle checkpoints can be
targets for oncogenic activation in cancer, whereas, nega-
tive regulators, such as tumor suppressor genes, are targets
for inactivation [10]. The observations made in the
present study reveals that the majority of the alterations in
the genes of cell cycle array belong to intracellular kinase
networks, cell cycle regulating kinases, transcription fac-
tors and transcription activators. Based on the observation
in the expression pattern in low grade and high grade gli-
omas, it can be suggested that the upregulation of cell
cycle activators are seen as an early event in glioma. Once
these cells become malignant, it is not the cell cycle acti-
vators alone that are involved in tumorigenesis that pro-
vide a bad prognosis. In an earlier study the authors
reported that the correlation of c-Myc with cellular prolif-
eration is dependent on tissue type and differentiation sta-
tus [20,21]. Therefore, understanding the molecular
details of cell cycle regulation and checkpoint abnormali-
ties in cancer could offer an insight into potential thera-
peutic strategies.
Mitogenic signals provided by upregulation of cyclins and
cyclin dependent kinases induce stress, which results in
the crosstalk of intracellular kinases. In the present study,
the transcripts of MAP Kinases, which belong to the intra-
cellular kinase network, are overexpressed in low-grade
gliomas. This overexpression in low grade gliomas may
lead to initiation of proliferation through MAP Kinase
pathway, which seems to be an early event in gliomas.
Proliferation through the MAP Kinase pathway is regu-
lated by Tyrosine kinases [22]. Plakoglobin (Pg) is the
only cytoplasmic protein component common to both
junctional complexes mediating cell-cell adhesion, adher-
ens junctions and desmosomes. It was found to be over-
expressed in low grade gliomas by 91-fold. The regulatory
functions of plakoglobin are still not well characterized.
However, it could be suggested that overexpression of
MAP Kinases and Plakoglobin is mediated by tyrosine
kinases in the pathogenesis of gliomas.
Functional genomics approach in brain tumor research
will help us to identify transcriptional aberrations that are
causative or are caused by brain neoplasia, which in turn
will facilitate the understanding of functionally relevant
pathways involved in brain tumor pathogenesis and pro-
vide for relevant prognostic, diagnostic, and/or therapeu-
tic tumor markers. Based on this limited experience, we
conclude that DNA macroarray analysis is a powerful tool
for studying the pathogenesis of gliomas.
Summary and Conclusion
Macroarray analysis of 114 cell cycle genes in different
grades of glioma indicated differential expression pattern
in 34% of the gene transcripts, when compared to thePublish with BioMed Central    and   every 
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normal tissue. Majority of the transcripts belong to the
intracellular kinase networks, cell cycle regulating kinases,
transcription factors and transcription activators. Based
on the observation in the expression pattern in low grade
and high grade gliomas, it can be suggested that the upreg-
ulation of cell cycle activators are seen as an early event in
glioma; however, in malignancy it is not the cell cycle acti-
vators alone, which are involved in tumorigenesis.
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